

PATIENT NAME: _____ DATE OF VISIT: _____

Use this checklist **before each infusion** to identify a patient who may be experiencing: new, changed, or worsened neurological, cognitive, or behavioral signs or symptoms. These signs and symptoms could be related to post-transplant lymphoproliferative disorder (PTLD), involving the central nervous system (CNS), or progressive multifocal leukoencephalopathy (PML). Both of these can cause death.

Remember to GIVE CARE (Give, Counsel, Ask, REmind) Check as completed:

GIVE

A copy of the NULOJIX Medication Guide must be provided to patients receiving NULOJIX before each infusion.

Gave Medication Guide

Counsel

Use the Medication Guide to counsel patients about the risks and benefits of NULOJIX, including:

- ◆ increased risk for PTLD, predominantly involving the CNS
- ◆ increased risk of PML, a CNS infection

Counseled patient

Ask

Read these questions aloud to the patient before starting each infusion.

1. Over the past month, have you had any new or worsening medical problems such as a new or sudden change in your thinking, memory, speech, mood, behavior, vision, balance, strength, or other problems?
2. Over the past month, have you had any new or worsening symptoms such as fever, night sweats, tiredness that does not go away, weight loss, or swollen glands?

1. Asked patient

Yes
No

2. Asked patient

Yes
No

If any response is YES, notify the prescriber to discuss the patient's symptoms.



REmind

Remind patients to immediately report any new or worsening medical problems such as:

- ◆ a new or sudden change in thinking, memory, speech, mood, behavior, vision, balance, strength
- ◆ fever, night sweats, tiredness that does not go away, weight loss, or swollen glands

Reminded patient

Please file this checklist in the patient's medical record.

Infusion administered

REPORTING ADVERSE EVENTS

For any adverse event with the use of NULOJIX, healthcare professionals should contact Bristol-Myers Squibb at 1-800-721-5072 and/or the FDA MedWatch program by phone at 1-800-FDA-1088 or online at www.fda.gov/medwatch/report.htm.

This document is not intended as a complete description of the risks associated with the use of NULOJIX. Please refer to the complete Prescribing Information and Medication Guide.

All REMS materials, including a NULOJIX[®] REMS webinar, are accessible at www.NULOJIX.com/REMS.aspx. For additional information, please call Bristol-Myers Squibb at 1-800-321-1335 or visit www.NULOJIX.com.